123 related articles for article (PubMed ID: 22925490)
1. Role of high dose rate brachytherapy in the treatment of prostate cancer.
Ghilezan M
Cancer Radiother; 2012 Sep; 16(5-6):418-22. PubMed ID: 22925490
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
5. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
[TBL] [Abstract][Full Text] [Related]
8. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy.
Yamada Y; Rogers L; Demanes DJ; Morton G; Prestidge BR; Pouliot J; Cohen GN; Zaider M; Ghilezan M; Hsu IC;
Brachytherapy; 2012; 11(1):20-32. PubMed ID: 22265435
[TBL] [Abstract][Full Text] [Related]
9. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
12. HDR brachytherapy combined with external beam radiation for localised prostate cancer: early experience from the Sydney Cancer Centre.
Whalley D; Patanjali N; Jackson M; Lovett A; Chatfield M; Hruby G
J Med Imaging Radiat Oncol; 2012 Apr; 56(2):220-6. PubMed ID: 22498197
[TBL] [Abstract][Full Text] [Related]
13. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
14. The role of high-dose rate brachytherapy in locally advanced prostate cancer.
Vicini FA; Vargas C; Edmundson G; Kestin L; Martinez A
Semin Radiat Oncol; 2003 Apr; 13(2):98-108. PubMed ID: 12728439
[TBL] [Abstract][Full Text] [Related]
15. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
Zaorsky NG; Den RB; Doyle LA; Dicker AP; Hurwitz MD
Expert Rev Med Devices; 2013 Nov; 10(6):751-63. PubMed ID: 24195459
[TBL] [Abstract][Full Text] [Related]
16. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
17. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
18. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
Morton G; Loblaw A; Cheung P; Szumacher E; Chahal M; Danjoux C; Chung HT; Deabreu A; Mamedov A; Zhang L; Sankreacha R; Vigneault E; Springer C
Radiother Oncol; 2011 Sep; 100(3):463-7. PubMed ID: 21924511
[TBL] [Abstract][Full Text] [Related]
19. High dose rate brachytherapy for prostate cancer.
Hoskin P
Cancer Radiother; 2008 Nov; 12(6-7):512-4. PubMed ID: 18755623
[TBL] [Abstract][Full Text] [Related]
20. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
Vargas CE; Martinez AA; Boike TP; Spencer W; Goldstein N; Gustafson GS; Krauss DJ; Gonzalez J
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):416-23. PubMed ID: 16879929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]